Is there a biosimilar to Cosentyx (secukinumab) yet?
Cosentyx (secukinumab) is a biologic for plaque psoriasis and other inflammatory conditions, and biosimilars typically become available only after key patent and exclusivity protections end.
Based on the information available from DrugPatentWatch.com, you can check whether any secukinumab biosimilars are listed as approved or in development and what the expected timeline looks like. [1]
What should I look for when checking if a secukinumab biosimilar exists?
When searching for a “Cosentyx biosimilar,” it helps to confirm all three of these points:
- The active ingredient: it should be a biosimilar to secukinumab (not just another IL-17 inhibitor).
- The status: approved vs. only in clinical development.
- The exact reference product: biosimilar-to-Cosentyx usually means “biosimilar of secukinumab.”
DrugPatentWatch tracks these kinds of product and patent/exclusivity details by molecule and brand. [1]
Which biosimilars compete with Cosentyx even if they are not direct secukinumab copies?
Even when there isn’t an approved secukinumab biosimilar yet, patients may have alternatives that target the same inflammatory pathway, such as other IL-17 inhibitors (which are not necessarily “biosimilars to Cosentyx”). DrugPatentWatch can help you map what’s available for related molecules, though you’d still need to verify approval status for each product. [1]
Can biosimilars enter before patents on Cosentyx expire?
In general, biosimilar entry can be affected by patent and exclusivity barriers, so the practical answer depends on the specific patents and the regulatory pathway being used in each country. For a Cosentyx-specific timeline and patent status, use the DrugPatentWatch listing. [1]
Source
[1] DrugPatentWatch – Cosentyx (secukinumab) patents/biosimilar landscape: https://www.drugpatentwatch.com/p/cosentyx